Da Li

Da Li

Auto-generated profile, based on publicly available information

Da Li

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
LSLai-Rong Song
Lai-Rong Song
JWJian-Cong Weng
Jian-Cong Weng
CLCheng-Bei Li
Cheng-Bei Li
XHXulei Huo
Xulei Huo
HLHuan Li
Huan Li
JZJunting Zhang
Junting Zhang
BACKGROUND: Lower-grade gliomas (LGGs) vary widely in terms of the patient’s overall survival (OS). There is no current, valid method that could exactly predict the survival. The effects of intratumoral immune infiltration on clinical outcome have been widely reported. Thus, we aim to develop an immune infiltration signature to predict the survival of LGG patients. METHODS: We analyzed 1216 LGGs from 5 public data sets, including 2 RNA sequencing data sets and 3 microarray data sets. Least absolute shrinkage and selection operator (LASSO) Cox regression was used to select an immune infiltration signature and build a risk score. The performance of the risk score was assessed in the training set (329 patients), internal validation set (140 patients), and 4 external validation sets (405, 118, 88, and 136 patients). RESULTS: An immune infiltration signature consisting of 20 immune metagenes was used to generate a risk score. The performance of the risk score was thoroughly verified in the training and validation sets. Additionally, we found that the risk score was positively correlated with the expression levels of TGF-β and PD-L1, which were important targets of combination immunotherapy. Furthermore, a nomogram incorporating the risk score, patient’s age, and tumor grade was developed to predict the OS, and it performed well in all the training and validation sets (C-index: 0.873, 0.881, 0.781, 0.765, 0.721, and 0.753). CONCLUSION: The risk score based on the immune infiltration signature has reliable prognostic and predictive value for patients with LGGs and is a potential biomarker for the cotargeting immunotherapy. FUNDING: This work was supported by The National Natural Science Foundation of China (grant nos. 81472370 and 81672506), the Natural Science Foundation of Beijing (grant no. J180005), the National High Technology Research and Development Program of China (863 Program, grant no. 2014AA020610), and the National Basic Research Program of China (973 Program, grant no. 2014CB542006).

1 September 2017 in Journal of Neurosurgery
Verified
Journal Article
Closed access
KTKai-Bing Tian
Kai-Bing Tian
JZJing-Jie Zheng
Jing-Jie Zheng
JMJun-Peng Ma
Jun-Peng Ma
SHShu-Yu Hao
Shu-Yu Hao
LWLiang Wang
Liang Wang
DLDa Li
Da Li
OBJECTIVE: The natural history of cerebral cavernous malformations (CMs) has been widely studied, but the clinical course of untreated thalamic CMs is largely unknown. Hemorrhage of these lesions can be devastating. The authors undertook this study to obtain a prospective hemorrhage rate and provide a better understanding of the prognosis of untreated thalamic CMs.METHODS: This longitudinal cohort study included patients with thalamic CMs who were diagnosed between 2000 and 2015. Clinical data were recorded, radiological studies were extensively reviewed, and follow-up evaluations were performed.RESULTS: A total of 121 patients were included in the study (56.2% female), with a mean follow-up duration of 3.6 years. The overall annual hemorrhage rate (subsequent to the initial presentation) was calculated to be 9.7% based on the occurrence of 42 hemorrhages over 433.1 patient-years. This rate was highest in patients (n = 87) who initially presented with hemorrhage and focal neurological deficits (FNDs) (14.1%) (χ2 = 15.358, p < 0.001), followed by patients (n = 19) with hemorrhage but without FND (4.5%) and patients (n = 15) without hemorrhage regardless of symptoms (1.2%). The initial patient presentations of hemorrhage with FND (hazard ratio [HR] 2.767, 95% CI 1.336–5.731, p = 0.006) and associated developmental venous anomaly (DVA) (HR 2.510, 95% CI 1.275–4.942, p = 0.008) were identified as independent hemorrhage risk factors. The annual hemorrhage rate was significantly higher in patients with hemorrhagic pres entation at diagnosis (11.7%, p = 0.004) or DVA (15.7%, p = 0.002). Compared with the modified Rankin Scale (mRS) score at diagnosis (mean 2.2), the final mRS score (mean 2.0) was improved in 37 patients (30.6%), stable in 59 patients (48.8%), and worse in 25 patients (20.7%). Lesion size (odds ratio [OR] per 0.1 cm increase 3.410, 95% CI 1.272–9.146, p = 0.015) and mRS score at diagnosis (OR per 1 point increase 3.548, 95% CI 1.815–6.937, p < 0.001) were independent adverse risk factors for poor neurological outcome (mRS score ≥ 2). Patients experiencing hemorrhage after the initial ictus (OR per 1 ictus increase 6.923, 95% CI 3.023–15.855, p < 0.001) had a greater chance of worsened neurological status.CONCLUSIONS: This study verified the adverse predictors for hemorrhage and functional outcomes of thalamic CMs and demonstrated an overall annual symptomatic hemorrhage rate of 9.7% after the initial presentation. These findings and the mode of initial presentation are useful for clinicians and patients when selecting an appropriate treatment, although the tertiary referral bias of the series should be taken into account.

18 March 2021 in Stroke and Vascular Neurology
Verified
Journal Article
Open access
PDF file
DLDa Li
Da Li
JZJing-Jie Zheng
Jing-Jie Zheng
JWJian-Cong Weng
Jian-Cong Weng
PLPanpan Liu
Panpan Liu
ZWZe-Yu Wu
Ze-Yu Wu
ZWZhen Wu
Zhen Wu
Background Haemorrhages of brainstem cavernous malformations (CMs) can lead to neurological deficits, the natural history of which is uncertain. The study aimed to evaluate the neurological outcomes of untreated brainstem CMs and to identify the adverse factors associated with worsened outcomes. Methods From 2009 to 2015, 698 patients (321 women) with brainstem CMs were entered into the prospective cohort after excluding patients lost to follow-up (n=43). All patients were registered, clinical data were collected and scheduled follow-up was performed. Results After a median follow-up of 60.9 months, prospective haemorrhages occurred in 167 patients (23.9%). The mean modified Rankin Scale scores at enrolment and at censoring time were 1.6 and 1.2. Neurological status was improved, unchanged and worsened in 334 (47.9%), 293 (42.0%) and 71 (10.2%) patients, respectively; 233 (33.4%) recovered to normal levels. Lesions crossing the axial midpoint (relative risk (RR) 2.325, p=0.003) and developmental venous anomaly (DVA) (RR 1.776, p=0.036) were independently significantly related to worsened outcomes. The percentage of worsened outcomes was 5.3% (18 of 337) in low-risk patients (neither DVA nor crossing the axial point) and increased to 26.0% (13 of 50) in high-risk patients (with both DVA and crossing the axial point). The percentage of worsened outcomes significantly increased as the number of prospective haemorrhages increased (from 1.5% (8 of 531, if 0 prospective ictus) to 37.5% (48 of 128, if 1 ictus) and 38.5% (15 of 39, if >1 ictus)). Conclusions The neurological outcomes of untreated brainstem CMs were improved/unchanged in majority of patients (89.8%) with a fatality rate of 1.7% in our cohort, which seemed to be favourable. Radiological features significantly predicted worsened outcomes. Our results provide evidence for clinical consultation and individualised treatment. The referral bias of our cohort was underlined.

1 September 2018 in World Neurosurgery
Verified
Journal Article
Closed access
GZGui-Jun Zhang
Gui-Jun Zhang
YZYun-Sheng Zhang
Yun-Sheng Zhang
GZGuo-Bin Zhang
Guo-Bin Zhang
XYXiu-Juan Yan
Xiu-Juan Yan
CLCheng-Bei Li
Cheng-Bei Li
JZJunting Zhang
Junting Zhang

1 April 2018 in World Neurosurgery
Verified
Journal Article
Closed access
GZGui-Jun Zhang
Gui-Jun Zhang
GZGuo-Bin Zhang
Guo-Bin Zhang
YZYun-Sheng Zhang
Yun-Sheng Zhang
HLHuan Li
Huan Li
CLCheng-Bei Li
Cheng-Bei Li
JZJunting Zhang
Junting Zhang

8 December 2018 in Neurosurgical Review
Verified
Journal Article
Closed access
PDF file
XMXiu-Jian Ma
Xiu-Jian Ma
DLDa Li
Da Li
LWLiang Wang
Liang Wang
SHShu-Yu Hao
Shu-Yu Hao
LZLi-Wei Zhang
Li-Wei Zhang
Zhen WuZhen Wu
Zhen Wu